parallel randomized trial

S003132

Design

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Empagliflozin SGLT2 inhibitor (empagliflozin 10 mg daily)	lifestyle: not reported		60
A2	Liraglutide 1.8 mg subcutaneous once daily GLP-1 agonist (liraglutide 1.8 mg daily)	lifestyle: not reported		60

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Empagliflozin A1	Liraglutide 1.8 mg subcutaneous once daily A2
age	mean (years)	58.3	59.2
hba1c	mean (percent)	8.3	8.2
sbp	mean (mmHg)	138	137
weight	mean (kg)	85.2	84.9

10 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

HbA1c change (2 lines; O01)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
24	A1	change	-0.7 percent			60	not stated; other; R0005412:Table 2
24	A2	change	-0.9 percent			60	not stated; other; R0005412:Table 2

Body weight change in kilograms (diabetes) (2 lines; O02)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
24	A1	change	-1.6 kg			60	not stated; other; R0005412:Table 2
24	A2	change	-3.4 kg			60	not stated; other; R0005412:Table 2

Systolic blood pressure change (2 lines; O05)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
24	A1	change	-3 mmHg			60	not stated; other; R0005412:Table 2
24	A2	change	-6 mmHg			60	not stated; other; R0005412:Table 2

Nausea (1 lines; O27A)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events	0			60	not stated; other; R0005412:Table 2

Vomiting (1 lines; O27B)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events	0			60	not stated; other; R0005412:Table 2

Diarrhea (1 lines; O27C)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events	0			60	not stated; other; R0005412:Table 2

Constipation (1 lines; O27D)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events	0			60	not stated; other; R0005412:Table 2